Researchers at UCLA’s Jonsson Comprehensive Cancer Center have discovered the mechanism by which an experimental drug, GCS-100, removes a protein from lymphoma cells that prevents the cells from responding to chemotherapy. This discovery revives hope in GCS-100, a drug that had begun in clinical trials years before but had been delayed indefinitely. The researchers hope GCS-100 can be combined with chemotherapy to create an effective treatment for diffuse large B cell lymphoma (DLBCL), the most common and aggressive form of non-Hodgkin lymphoma, a cancer of the immune system. Read more here.
Study mentioned: Clark MC, et al. Galectin-3 binds to CD45 on diffuse large B cell lymphoma cells to regulate susceptibility to cell death. Blood. 2012 Oct 12. [Epub ahead of print] PMID: 23065155
No comments:
Post a Comment